Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376920 | 1.00 | CYP1A2 (0.66) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL11235716 | 0.92 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL19971590 | 0.91 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL30540821 | 0.91 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL10519082 | 0.90 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL1345017 | 0.89 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL10618700 | 0.89 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL15999499 | 0.87 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL10766497 | 0.87 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E | |
| SCHEMBL13368169 | 0.87 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19CLEC4MKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-111208221-B | Method for detecting lomefloxacin hydrochloride related substances | 宜宾市南溪区红光制药有限公司 | 2022-07-05 | — | — | CN | claimed |
| JP-2231477-A | — | — | None | — | — | JP | disclosed |
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-111208221-B | Method for detecting lomefloxacin hydrochloride related substances | 宜宾市南溪区红光制药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-111208221-B | Method for detecting lomefloxacin hydrochloride related substances | 宜宾市南溪区红光制药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114609260-A | Method for detecting lomefloxacin hydrochloride intermediate related substances | 江苏吉贝尔药业股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-111208221-A | Method for detecting lomefloxacin hydrochloride related substances | 宜宾市南溪区红光制药有限公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-111208221-A | Method for detecting lomefloxacin hydrochloride related substances | 宜宾市南溪区红光制药有限公司 | 2020-05-29 | — | — | CN | disclosed |
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | WANG RONGFU (US) | 2016-02-04 | — | — | US | disclosed |
| EP-0265230-A1 | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4665079-A | QUINOLINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4638067-A | NAPHTHYRIDINE AND QUINOLINE CARBOXYLIC ACIDS | WARNER-LAMBERT CO. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0172651-A1 | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
| US-4571396-A | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0159174-A2 | Substituted naphthyridine-, quinoline- and benzoxazine- carboxylic acids as antibacterial agents and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-10-23 | — | — | EP | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0106489-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
| US-4398029-A | BACTERICIDES | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030443-A1 | METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION | IRAK4, TLR8, TLR4 | CYP1A2 3095/4885CYP3A4 826/4885CYP2C19 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.